Conflicts of interest: None declared.
Thalidomide in the management of epidermolysis bullosa pruriginosa
Version of Record online: 8 JUN 2005
British Journal of Dermatology
Volume 152, Issue 6, pages 1332–1334, June 2005
How to Cite
Ozanic Bulic, S., Fassihi, H., Mellerio, J.E., McGrath, J.A. and Atherton, D.J. (2005), Thalidomide in the management of epidermolysis bullosa pruriginosa. British Journal of Dermatology, 152: 1332–1334. doi: 10.1111/j.1365-2133.2005.06492.x
- Issue online: 8 JUN 2005
- Version of Record online: 8 JUN 2005
- Accepted for publication 11 October 2004
- epidermolysis bullosa;
Epidermolysis bullosa (EB) pruriginosa is a distinctive clinical subtype of dystrophic EB. We report a patient with dominant dystrophic EB pruriginosa, who had an excellent response to systemic thalidomide treatment. The mechanism of action of thalidomide in the management of pruriginous disorders is not yet completely understood. Most recent studies point towards an immunomodulatory action of thalidomide that may suppress excessive production of tumour necrosis factor-α and may downregulate certain cell surface adhesion molecules involved in leucocyte migration.